The KPMG 2024 Life Sciences CEO Outlook report reveals that despite economic and geopolitical uncertainties, many CEOs remain optimistic. Growth prospects, new technologies, business models, and sustainability all feature within the report.

79% of CEOs expressed confidence in their companies' growth, with many planning to expand their workforce and engage in acquisitions. Generative AI emerges as a top investment priority, with 60% of CEOs focusing on it to drive innovation and efficiency - although concerns about regulatory challenges persist.

Sustainability and ESG strategies are crucial, yet only 43% of CEOs feel confident in meeting net zero goals by 2030. The sector acknowledges the importance of ESG for building trust and attracting talent but struggles with rapidly changing stakeholder expectations.

Workforce challenges also loom large, particularly in replacing retiring employees and enhancing diversity and inclusion. CEOs see achieving gender equity in leadership as vital for growth.

For more, please find the original story source here.